Consistent with these observations, this study also shows that the relapse-free survival of patients with basal-like breast cancers expressing high AnxA6 or low GRF2 is significantly poorer than that for patients expressing low AnxA6 or high GRF2 [17]. This evidence concerns the gene RASGRF2 and breast carcinoma.